Alcon Files Investor Deck for $1.5B STAAR Acquisition

By Patricia Miller

Nov 04, 2025

2 min read

Alcon AG (NYSE:ALC) has filed an investor presentation regarding its proposed acquisition of STAAR Surgical Company (NASDAQ:STAA) with the U.S. Securities and Exchange Commission. This move aims to support engagement with STAAR stockholders.

Alcon’s proposal to acquire STAAR for $28.00 per share in cash, valuing the company at approximately $1.5 billion, represents about a 59 % premium to STAAR’s 90-day volume-weighted average price and a 51 % premium to its pre-announcement close on August 4, 2025.

STAAR’s investor materials emphasize that the offer premium exceeds the median premium of comparable MedTech transactions. Meanwhile, Alcon and STAAR have faced opposition from Broadwood Partners, STAAR’s largest shareholder, which has campaigned against the transaction and proposed replacing members of STAAR’s board.

Alcon asserts that its proposal delivers immediate and certain value for shareholders and supports continued innovation in ophthalmic technologies. The merger agreement includes a 45-day window-shop period, allowing STAAR to consider superior offers, which Alcon argues provides a fair process to confirm the best outcome for shareholders.

This release follows ongoing filings related to the proposed transaction, including STAAR’s definitive proxy statement filed with the SEC on September 16, 2025. STAAR’s special meeting of stockholders has been postponed to December 3, 2025, to allow additional time for shareholder engagement.

#Investor Takeaway

Alcon’s $28 per-share cash offer may represent strong near-term value for STAAR shareholders amid continued debate over strategic direction.

#Market Impact

The proposed acquisition continues to influence STAAR’s share price and investor sentiment, particularly given the opposition campaign by Broadwood Partners. Markets will watch closely how shareholder voting and potential alternative bids affect valuation.

#What’s Next

Investors should monitor STAAR’s upcoming December 3 special meeting and any further SEC filings or updates related to competing proposals and merger conditions.

Important Notice And Disclaimer

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.